PURPOSE: To evaluate and compare the efficacy of posterior subtenon's @entity2713 injections versus grid laser photocoagulation (GLP) combined with posterior subtenon's @entity2713 injection in eyes with @entity1103 ( @entity1103 ). METHODS: In this prospective clinical study, 42 eyes with @entity1103 that showed a decrease in visual acuity (VA) were included. The first group consisted of 22 eyes that received a posterior subtenon's injection of 40   mg of @entity2995 under topical anesthesia. The second group of 20 eyes received macular GLP applied 1 month after subtenon's @entity2995 (STTA) injection. All @entity1 were evaluated at baseline and 1 day; 1, 2, 4, 6, and 8 weeks; and 3 and 6 months after injection. In some @entity1 , injections were repeated after 3 months. The main outcome measures were VA, @entity1020 ( @entity1020 ), intraocular pressure, @entity231 progression, and frequency of complications. RESULTS: The mean baseline @entity1020 for Group I was 456.85  56.90    m. The mean baseline @entity1020 for Group II was 455.66  57    m. In the first group, mean CMTs for second week, 8th week, 12th week, and 6th month were 258.15, 276.50, 280.05, and 433.30    m, respectively. In the second group, mean CMTs for second week, 8th week, 12th week, and 6th month were 261.42, 272.76, 284.71, and 291.76    m, respectively. Before treatment, in the first group, the mean best-corrected visual acuity (BCVA) measured using a Snellen chart was 0.19, while the first week, third, and sixth month BCVA means were 0.59, 0.57, and 0.41, respectively. Before treatment, BCVA in the second group was 0.17, while the first week, third, and sixth month means were 0.61, 0.64, and 0.60, respectively. Treatment complications included @entity231 in 4 eyes and @entity726 in 1 eye. CONCLUSION: There is a temporary therapeutic effect of posterior subtenon's @entity2713 injection without laser photocoagulation. GLP improves VA and reduces the risk of recurrent @entity1103 after posterior STTA injection.

Posterior Subtenon's Capsule @entity2995 Injection for the Treatment of XXXX .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity2995 :: ('MESH:D014222', 'Chemical') :: ['triamcinolone acetonide'] @entity231 :: ('MESH:D002386', 'Disease') :: ['cataracts', 'cataract'] @entity726 :: ('MESH:D005901', 'Disease') :: ['glaucoma'] @entity1103 :: ('MESH:D008269', 'Disease') :: ['macular edema', 'DME', 'diabetic macular edema'] @entity1020 :: ('MESH:D008268', 'Disease') :: ['CMT', 'central macular thickness'] @entity2713 :: ('MESH:D014221', 'Chemical') :: ['triamcinolone']
@entity1103 :: (MESH:D008269,Disease) :: ['Diabetic Macular Edema']
